| Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ... Cancer discovery 13 (7), 1556-1571, 2023 | 43 | 2023 |
| The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy JB Hines, AJ Kacew, RF Sweis Current Oncology Reports 25 (3), 189-199, 2023 | 23 | 2023 |
| Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: A case report J Hines, E Daily, AK Pham, CR Shea, U Nadeem, AN Husain, WM Stadler, ... Journal of Medical Case Reports 15, 1-6, 2021 | 6 | 2021 |
| Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of … A Nuccio, G Viscardi, F Salomone, A Servetto, FM Venanzi, ST Riva, ... European Journal of Cancer 195, 113404, 2023 | 3 | 2023 |
| Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer JB Hines, B Bowar, E Levine, A Esposito, MC Garassino, CM Bestvina International Journal of Molecular Sciences 24 (11), 9429, 2023 | 3 | 2023 |
| Barriers and Resident Attitudes Surrounding Care of Patients with Sickle Cell Disease D Anderson, E Hickey, S Syed, J Hines, N Abou Baker Blood 136, 21-22, 2020 | 2 | 2020 |
| Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer. JB Hines, RB Cameron, A Esposito, L Kim, L Porcu, A Nuccio, G Viscardi, ... Journal of Thoracic Oncology, 2024 | 1 | 2024 |
| Understanding Hydroxyurea Utilization in Sickle Cell Disease: Exploring Patient and Provider Attitudes and Beliefs D Anderson, S Syed, P Ang, C Agwu, K Lien, J Hines, N Abou Baker Blood 140 (Supplement 1), 7879-7880, 2022 | 1 | 2022 |
| Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune … ME Devitt, RS Abraham, J Hines, BJ Horton, CE Fadul, JM Larner, ... Journal of Clinical Oncology 36 (15_suppl), 2010-2010, 2018 | 1 | 2018 |
| Pathologic endpoints as surrogates for survival endpoints in neoadjuvant immunotherapy clinical trials for non-small cell lung cancer RB Cameron, JB Hines, A Esposito, C Bestvina, MC Garassino, V Torri, ... Cancer Research 84 (6_Supplement), 3638-3638, 2024 | | 2024 |
| Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint … JB Hines, RB Cameron, A Esposito, L Kim, L Porcu, A Nuccio, G Viscardi, ... Journal of Thoracic Oncology, 2024 | | 2024 |
| P1. 25-02 Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis J Hines, R Cameron, V Torri, T Cascone, PM Forde, A Esposito, E Vokes, ... Journal of Thoracic Oncology 18 (11), S268, 2023 | | 2023 |
| What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? RB Cameron, JB Hines, V Torri, L Porcu, J Donington, CM Bestvina, ... Therapeutic Advances in Medical Oncology 15, 17588359231198446, 2023 | | 2023 |
| Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma. S Syed, J Hines, R Baccile, SJ Rouhani, P Reid Journal of Clinical Oncology 41 (16_suppl), 2637-2637, 2023 | | 2023 |
| Molecular determinants of KRAS p. G12C inhibitor efficacy in advanced NSCLC MV Negrao, HA Araujo, G Lamberti, AJ Cooper, T Zhou, N Akhave, ... Cancer Research 83 (7_Supplement), 3431-3431, 2023 | | 2023 |
